Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

Omid C. Farokhzad, Jianjun Cheng, Benjamin A. Teply, Ines Sherifi, Sangyong Jon, Philip W. Kantoff, Jerome P. Richie, Robert Langer

Research output: Contribution to journalArticle

1323 Citations (Scopus)

Abstract

Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A 10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004). The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 ± 4% vs. 18 ± 5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, respectively (mean ± SD); n = 7]. After a single intratumoral injection of Dtxl-NP-Apt bioconjugates, complete tumor reduction was observed in five of seven LNCaP xenograft nude mice (initial tumor volume of ≈300 mm 3), and 100% of these animals survived our 109-day study. In contrast, two of seven mice in the Dtxl-NP group had complete tumor reduction with 109-day survivability of only 57%. Dtxl alone had a survivability of only 14%. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.

Original languageEnglish (US)
Pages (from-to)6315-6320
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number16
DOIs
StatePublished - Apr 18 2006

Fingerprint

docetaxel
Nanoparticles
Drug Therapy
Neoplasms
Weight Loss
Prostatic Neoplasms
Body Weight
Nucleotide Aptamers
antineoplaston A10
Tumor Burden
Heterografts

Keywords

  • Docetaxel
  • Poly(D,-Llactic-co-glycolic acid) (PLGA)
  • Prostate cancer
  • Prostate-specific membrane antigen
  • Targeted delivery

ASJC Scopus subject areas

  • General

Cite this

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. / Farokhzad, Omid C.; Cheng, Jianjun; Teply, Benjamin A.; Sherifi, Ines; Jon, Sangyong; Kantoff, Philip W.; Richie, Jerome P.; Langer, Robert.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 16, 18.04.2006, p. 6315-6320.

Research output: Contribution to journalArticle

Farokhzad, Omid C. ; Cheng, Jianjun ; Teply, Benjamin A. ; Sherifi, Ines ; Jon, Sangyong ; Kantoff, Philip W. ; Richie, Jerome P. ; Langer, Robert. / Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 16. pp. 6315-6320.
@article{c4b2ffad0c0343f3be691f1ba56cb311,
title = "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo",
abstract = "Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A 10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004). The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 ± 4{\%} vs. 18 ± 5{\%} for Dtxl-NP-Apt vs. Dtxl-NP at nadir, respectively (mean ± SD); n = 7]. After a single intratumoral injection of Dtxl-NP-Apt bioconjugates, complete tumor reduction was observed in five of seven LNCaP xenograft nude mice (initial tumor volume of ≈300 mm 3), and 100{\%} of these animals survived our 109-day study. In contrast, two of seven mice in the Dtxl-NP group had complete tumor reduction with 109-day survivability of only 57{\%}. Dtxl alone had a survivability of only 14{\%}. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.",
keywords = "Docetaxel, Poly(D,-Llactic-co-glycolic acid) (PLGA), Prostate cancer, Prostate-specific membrane antigen, Targeted delivery",
author = "Farokhzad, {Omid C.} and Jianjun Cheng and Teply, {Benjamin A.} and Ines Sherifi and Sangyong Jon and Kantoff, {Philip W.} and Richie, {Jerome P.} and Robert Langer",
year = "2006",
month = "4",
day = "18",
doi = "10.1073/pnas.0601755103",
language = "English (US)",
volume = "103",
pages = "6315--6320",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

AU - Farokhzad, Omid C.

AU - Cheng, Jianjun

AU - Teply, Benjamin A.

AU - Sherifi, Ines

AU - Jon, Sangyong

AU - Kantoff, Philip W.

AU - Richie, Jerome P.

AU - Langer, Robert

PY - 2006/4/18

Y1 - 2006/4/18

N2 - Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A 10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004). The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 ± 4% vs. 18 ± 5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, respectively (mean ± SD); n = 7]. After a single intratumoral injection of Dtxl-NP-Apt bioconjugates, complete tumor reduction was observed in five of seven LNCaP xenograft nude mice (initial tumor volume of ≈300 mm 3), and 100% of these animals survived our 109-day study. In contrast, two of seven mice in the Dtxl-NP group had complete tumor reduction with 109-day survivability of only 57%. Dtxl alone had a survivability of only 14%. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.

AB - Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A 10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004). The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo [body weight loss of 7.7 ± 4% vs. 18 ± 5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, respectively (mean ± SD); n = 7]. After a single intratumoral injection of Dtxl-NP-Apt bioconjugates, complete tumor reduction was observed in five of seven LNCaP xenograft nude mice (initial tumor volume of ≈300 mm 3), and 100% of these animals survived our 109-day study. In contrast, two of seven mice in the Dtxl-NP group had complete tumor reduction with 109-day survivability of only 57%. Dtxl alone had a survivability of only 14%. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.

KW - Docetaxel

KW - Poly(D,-Llactic-co-glycolic acid) (PLGA)

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=33646582037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646582037&partnerID=8YFLogxK

U2 - 10.1073/pnas.0601755103

DO - 10.1073/pnas.0601755103

M3 - Article

C2 - 16606824

AN - SCOPUS:33646582037

VL - 103

SP - 6315

EP - 6320

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -